Thompson Siegel & Walmsley’s Xeris Biopharma Holdings XERS Stock Holding History

Thompson Siegel & Walmsley’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$509K	Sell	64,320 -22,000	-25%	-$140K	0.01%	361
2026 Q1	$501K	Sell	86,320 -14,564	-14%	-$96.6K	0.01%	358
2025 Q4	$792K	Hold	100,884	–	–	0.01%	325
2025 Q3	$821K	Sell	100,884 -165,503	-62%	-$1.1M	0.01%	324
2025 Q2	$1.24M	Buy	266,387 +93,603	+54%	+$429K	0.02%	291
2025 Q1	$949K	Buy	172,784 +20,000	+13%	+$80.7K	0.02%	288
2024 Q4	$518K	Sell	152,784 -20,000	-12%	-$64.3K	0.01%	316
2024 Q3	$492K	Hold	172,784	–	–	0.01%	323
2024 Q2	$389K	Sell	172,784 -17,216	-9%	-$34.7K	0.01%	315
2024 Q1	$420K	Buy	+190,000	New	+$492K	0.01%	307
2021 Q3	–	Sell	-62,000	Closed	-$252K	–	749
2021 Q2	$252K	Buy	62,000 +17,000	+38%	+$64.9K	﹤0.01%	354
2021 Q1	$203K	Buy	45,000 +43,750	+3,500%	+$236K	﹤0.01%	353
2020 Q4	$6K	Buy	+1,250	New	+$6.25K	﹤0.01%	631

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Thompson Siegel & Walmsley's XERS Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its Xeris Biopharma Holdings (XERS) stake by 25% in Q2 2026, selling an estimated $140K and leaving 64,320 shares worth $509K. The position accounts for 0.01% of the portfolio, ranked #361.

Thompson Siegel & Walmsley first reported a position in XERS in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.24M in Q2 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Thompson Siegel & Walmsley held 64,320 shares of Xeris Biopharma Holdings worth $509K as of Q2 2026.
Thompson Siegel & Walmsley sold 22,000 Xeris Biopharma Holdings shares in Q2 2026, an estimated $140K.
Xeris Biopharma Holdings made up 0.01% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #361 holding.
Thompson Siegel & Walmsley first reported a position in Xeris Biopharma Holdings in Q4 2020 and has held it in 13 quarters since.
Thompson Siegel & Walmsley's Xeris Biopharma Holdings position peaked at $1.24M in Q2 2025.
239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.